WealthPlan Investment Management LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 80.6% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 11,376 shares of the company’s stock after selling 47,194 shares during the period. WealthPlan Investment Management LLC’s holdings in Johnson & Johnson were worth $486,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of JNJ. Moneta Group Investment Advisors LLC lifted its holdings in Johnson & Johnson by 90,144.4% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after purchasing an additional 54,326,454 shares during the period. Norges Bank bought a new stake in shares of Johnson & Johnson during the 4th quarter worth about $4,609,399,000. Providence Capital Advisors LLC lifted its stake in shares of Johnson & Johnson by 141,974.0% in the 1st quarter. Providence Capital Advisors LLC now owns 4,750,956 shares of the company’s stock worth $30,651,000 after acquiring an additional 4,747,612 shares during the period. Morgan Stanley increased its stake in shares of Johnson & Johnson by 12.0% during the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after acquiring an additional 4,521,062 shares during the period. Finally, BlackRock Inc. raised its holdings in Johnson & Johnson by 1.4% during the first quarter. BlackRock Inc. now owns 201,491,567 shares of the company’s stock worth $31,231,193,000 after purchasing an additional 2,688,798 shares in the last quarter. Institutional investors own 68.40% of the company’s stock.
Insider Buying and Selling
In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of the stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the sale, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, insider William Hait sold 14,698 shares of the company’s stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the transaction, the insider now directly owns 87,747 shares of the company’s stock, valued at $15,092,484. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the transaction, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The disclosure for this sale can be found here. 0.20% of the stock is owned by insiders.
Johnson & Johnson Stock Up 0.3 %
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The company had revenue of $25.53 billion for the quarter, compared to analyst estimates of $24.63 billion. During the same quarter last year, the firm earned $2.59 EPS. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. On average, analysts predict that Johnson & Johnson will post 10.02 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Investors of record on Monday, August 28th were given a $1.19 dividend. The ex-dividend date of this dividend was Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.03%. Johnson & Johnson’s dividend payout ratio is 96.36%.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on JNJ. Stifel Nicolaus boosted their price objective on Johnson & Johnson from $165.00 to $175.00 in a research note on Friday, July 21st. Credit Suisse Group boosted their price target on shares of Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, July 21st. Wells Fargo & Company lowered their price objective on shares of Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating on the stock in a research note on Thursday, August 31st. Barclays increased their target price on shares of Johnson & Johnson from $158.00 to $162.00 and gave the company an “equal weight” rating in a research note on Thursday. Finally, Morgan Stanley upped their price target on Johnson & Johnson from $172.00 to $174.00 and gave the company an “equal weight” rating in a report on Wednesday, October 11th. Eight investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $171.00.
Get Our Latest Stock Analysis on Johnson & Johnson
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- MarketBeat Week in Review – 10/9 – 10/13
- NYSE Stocks Give Investors a Variety of Quality OptionsÂ
- What BlackRock’s Earnings Tell You About The Stock Market Tide
- How to Find Undervalued Stocks
- Sociedad Quimica y Minera de Chile Well Positioned Lithium Stock
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
